Matinas Biopharm - MTNB STOCK NEWS

Matinas BioPharma (MTNB) has received a unanimous recommendation from the Data and Safety Monitoring Board (DSMB) to progress to the second cohort of its EnACT study for MAT2203, an oral formulation of amphotericin B aimed at treating cryptococcal meningitis. Enrollment for the 40 patient cohort will begin soon, with the next DSMB review expected in mid-2021. MAT2203 has also been designated as a Qualified Infectious Disease Product and has Fast Track status from the FDA, enhancing its potential for addressing significant unmet medical needs.

Matinas BioPharma (MTNB) announced positive outcomes from its End of Phase 2 meeting with the FDA regarding MAT9001, an omega-3 therapy for severe hypertriglyceridemia (SHTG). The FDA agreed on the requirement for a single Phase 3 trial lasting 12 weeks, which will support a New Drug Application (NDA). Matinas aims to initiate this Phase 3 program in the first half of 2021. The alignment with FDA provides clarity for the registration pathway and the company anticipates upcoming data from its ENHANCE-IT trial against Vascepa, potentially differentiating MAT9001 and underscoring its clinical benefits.

Matinas BioPharma Holdings, Inc. (MTNB) has appointed Natasha Giordano as an independent director effective September 14, 2020. With over 25 years in healthcare leadership, her expertise will strengthen the board as the company advances its clinical development. Current board member Adam Stern will transition to a consulting role after the Annual Meeting of Stockholders on November 2, 2020, having served since the company's inception. The changes are seen as strategic moves to enhance shareholder value and support upcoming product milestones.

Matinas BioPharma Holdings (NYSE AMER: MTNB) announced that CEO Jerome D. Jabbour will join a panel at Maxim Group’s M-VEST Virtual Conference on September 17, 2020. The discussion, titled A Too Quiet Pandemic – Fungal Disease, will be moderated by analyst Jason McCarthy, Ph.D., and is set for 11:00 a.m. ET. A live audio webcast will be available on the company's website. Matinas focuses on developing therapeutics for unmet medical needs and is advancing its lead candidates, including MAT9001 and MAT2203.

Matinas BioPharma (MTNB) completed enrollment in the ENHANCE-IT Study, evaluating MAT9001 against Vascepa for reducing triglyceride levels. This head-to-head study focuses on the pharmacodynamic effects of MAT9001 and aims to establish its clinical efficacy. Topline data is expected in Q1 2021. The trial includes male and female adults with elevated triglycerides and is conducted at eight U.S. sites. The successful enrollment, achieved in under three months, is seen as a key milestone for the company, promising valuable insights into the omega-3 treatment landscape.

Matinas BioPharma Holdings (MTNB) announced that CEO Jerome D. Jabbour will present at two virtual investor conferences. The first is the LD Micro Virtual Conference on September 2, 2020, at 12:00 p.m. ET, and the second is the HC Wainwright 22nd Annual Global Investment Conference on September 16, 2020, at 12:30 p.m. ET. Both presentations will have live webcasts available on the company’s investor relations page, with replays accessible for 90 days. Matinas is focused on developing MAT9001 for cardiovascular conditions and MAT2203 for invasive fungal infections.

Matinas BioPharma Holdings (MTNB) announced positive results from the Phase 1 portion of the EnACT study for MAT2203, an oral formulation of amphotericin B for cryptococcal meningitis. Published in Antimicrobial Agents and Chemotherapy, the trial demonstrated good safety and tolerability, with reduced toxicity compared to IV amphotericin B. The ongoing Phase 2 trial aims to further evaluate MAT2203's effectiveness in treating HIV-infected patients. MAT2203 has received FDA's QIDP and orphan drug designations, signaling its potential market impact.

Matinas BioPharma Holdings (MTNB) reports second quarter financial results for 2020, continuing progress in key clinical studies while facing challenges from the COVID-19 pandemic. The ENHANCE-IT study of MAT9001 and the EnACT study of MAT2203 have resumed enrollment, with topline data from the former expected in Q1 2021. As of June 30, 2020, the company reported $68 million in cash, up from $27.8 million at the end of 2019, despite a net loss of $5.8 million. Management is optimistic about upcoming catalysts and plans to host a conference call on August 10, 2020.

Matinas BioPharma Holdings (NYSE: MTNB) announced that CEO Jerome D. Jabbour will participate in a fireside chat at the BTIG Virtual Biotech Conference on August 11, 2020, at 9:00 a.m. ET. He will also host investor meetings during the event. Interested investors can contact the conference coordinator for arrangements. A live webcast of the discussion will be available on the Company's website, with a replay accessible for 90 days. Matinas BioPharma focuses on developing MAT9001 for cardiovascular conditions and MAT2203 for serious fungal infections.